Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:acquired_by |
gptkb:Shire_plc
|
| gptkbp:acquisition_year |
gptkb:2014
|
| gptkbp:clinical_trial |
multiple
|
| gptkbp:employees |
approximately 200
|
| gptkbp:focus_area |
rare diseases
|
| gptkbp:founded |
gptkb:1994
|
| gptkbp:founder |
Daniel J. Adams
|
| gptkbp:headquarters |
gptkb:Exton,_Pennsylvania
|
| https://www.w3.org/2000/01/rdf-schema#label |
Viro Pharma
|
| gptkbp:marketed_as |
gptkb:Cinryze
Vancocin |
| gptkbp:notable_products |
gptkb:Cinryze
Vancocin |
| gptkbp:partnerships |
various pharmaceutical companies
|
| gptkbp:research_focus |
antiviral therapies
|
| gptkbp:revenue |
over $200 million
|
| gptkbp:stock_exchange |
gptkb:NASDAQ
|
| gptkbp:stock_symbol |
VPHM
|
| gptkbp:bfsParent |
gptkb:Cinryze
|
| gptkbp:bfsLayer |
6
|